Generated by AI
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.
Website730 Third Avenue
New York, NY, 10017
United States
The latest articles about SNDX.
Summary of Nov 3's posts. Generated by AI.
Summary of Jul 14's posts. Generated by AI.
Summary of May 26's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about SNDX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.